ClinicalTrials.gg
WithdrawnNCT01815723Updated Aug 9, 2016

Efficacy Study on Dimethyl Fumarate to Treat Moderate to Severe Plaque Psoriasis

A Phase 3 interventional study of FP187 and Dimethyl fumarate in Plaque Psoriasis, sponsored by Forward-Pharma GmbH. Withdrawn at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-09.

Sponsored by Forward-Pharma GmbH · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 303 studies in Psoriasis with a site in Canada — 15 open to participants now, 32 under way, 14 of them phase 3. Psoriasis · Canada.

Enrollment
271st of 272
0 · median 227
Started
2016
with 14 others
Phase 3
139 of 303
4 open now
Registered
119th of 303
by date

Among the 303 studies in Psoriasis with a site in Canada, this one is the 271st largest by enrollment of the 272 interventional ones that give a count, is one of 15 that started in 2016, is one of 139 in phase 3, and was the 119th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

15 of the 303 studies in Psoriasis with a site in Canada are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 303 studies in Psoriasis with a site in Canada, or all of them as a file.
02

Study summary

This multicenter, randomised, double-dummy, Fumaderm® and placebo-controlled, parallel-group study will compare the efficacy and safety of 500 mg of FP187 (250 mg twice daily) compared to 720 mg Fumaderm® (240 mg three times daily) over 20 weeks of treatment. After an initial wash-out non-drug treatment phase of 1 to 6 weeks, all patients will receive allocated Study treatment up-titrated to the relevant dose level (i.e., 500 mg daily FP187, 720 mg daily Fumaderm®, or placebo). The up-titration to full dose will last 4 weeks for FP187 and 9 weeks for Fumaderm®. After 20 weeks of treatment, all patients will be asked to enter a separate open label treatment protocol expected to continue for up to 5 years.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • Psoriasis
  • Dimethyl fumarate
  • Fumaderm®
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, >=18 years of age;
  • clinical diagnosis of stable moderate to severe plaque psoriasis for at least 6 months;
  • clinical diagnosis of plaque psoriasis with an affected body surface area of no less than 10% and least 10 on the PASI scale and on the sPGA score at least as moderate;
  • Besides psoriasis, patient is in good general health
  • Patients with a DLQI score of at least 10

Exclusion criteria

Exclusion Criteria:

  • Pustular forms of psoriasis, erythrodermic or guttate psoriasis;
  • Known diseases;
  • Presence of another serious or progressive disease including skin ;
  • Active skin disease;
  • Use of topical medical treatment or UVB treatment during the 2 weeks preceding randomization;
  • Use of systemic anti-psoriatic treatment preceding randomization: methotrexate, cyclosporine, or PUVA (psoralen + UVA treatment) treatment within 4 weeks; biological treatment within 12 weeks; Stelara within 20 weeks; acitretin within 6 months;
  • Treatment with Fumaderm® or other Dimethyl Fumarate containing products within 12 weeks prior randomization;
  • Treatment with drugs influencing the course of psoriasis (e.g., antimalarial drugs, lithium) within 4 weeks prior to randomization;
  • Treatment with retinoids, other immunosuppressive treatment, cytostatics or drugs with known harmful effects on the kidneys within 3 months prior to randomization;
  • On-going stomach or intestinal problems;
  • (AST), Alanine transaminase (ALT) > 2 x upper normal limit (), or Gamma-glutamyltransferase (γ-GT) > 2.5 x ULN;
  • \< 60 ml/min;
  • Leucopenia, eosinophilia or lymphopenia;
  • Protein in the urine test;
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    FP187

    500 mg FP187 daily (250 mg twice daily)

    Drug: FP187 · Drug: Fumaderm® placebo

  • Active comparator
    Dimethyl fumarate

    720 mg Fumaderm® daily (240 mg three times daily)

    Drug: Dimethyl fumarate · Drug: FP187 placebo

  • Placebo comparator
    Placebo

    Matching FP187 and Fumaderm® placebo

    Drug: FP187 placebo · Drug: Fumaderm® placebo

Interventions

  • DrugFP187

    500 mg FP187 daily, two tablets of 125 mg twice daily, from 125 mg daily up-titrated to full dose over a 4-week phase, total treatment phase of 20 weeks

  • 720 mg Fumaderm® daily, two tablets of 120 mg three times daily, from 30 mg daily up-titrated to full dose over a 9-week phase, total treatment phase of 20 weeks

    Also known as: Fumaderm®

  • DrugFP187 placebo

    FP187 matching placebo tablets in the same regimen as for FP187 arm

  • DrugFumaderm® placebo

    Fumaderm® matching placebo tablets in the same regimen as for Fumaderm® arm

06

What researchers measure

Primary outcomes

  1. Proportion of patients achieving a 75% reduction in their Psoriasis Area and Severity Index (PASI75) score from baseline

    Time frame: after 20 weeks of treatment

  2. Responder rate of Static Physician's Global Assessment (sPGA)

    Achieving a score of clear or almost clear or a 2 step improvement on a 6-point scale as compared to baseline.

    Time frame: after 20 weeks of treatment

07

Study locations

1 site
  • Probity Medical Research
    Waterloo, Ontario N2J 1C4, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2016, a primary completion of Jun 2017 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2013
First posted
Mar 21, 2013
Start
Jun 2016
Primary completionEst.
Jun 2017
CompletionEst.
Jun 2017
Last update
Aug 9, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01815723
Lead sponsor
Forward-Pharma GmbH
Responsible party
Sponsor
First posted
Mar 21, 2013
Start date
Jun 2016
Primary completion
Jun 2017 (estimated)
Completion
Jun 2017 (estimated)
Last update
Aug 9, 2016

Study contacts

Kim A. Papp, MD
principal investigator · Probity Medical Research
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dimethyl Fumarate

Start the discussion